LINKS
ABOUT

davidlubaroff@ohanavaccines.com

Tel: 319-621-7206

David M. Lubaroff, PhD; Founder & Chief Scientific Officer

© 2023 by Ohana Vaccines

Ohana Vaccines, LLC

Ohana Vaccines uses a proprietary prime-boost strategy to cause the destruction of established prostate cancer

IMMUNOTHERAPY

IS THE NEW SOLUTION

OPPORTUNITY

With an estimated $19B total prostate cancer treatment cost by 2020, Ohana Vaccine targets the 20-30% of recurrent prostate cancer.

RAPID GROWTH

Ohana Vaccines is on track to complete clinical trials by the end of 2018 and is ready to scale rapidly to production.

QUICK RETURN

A patent is already filed and there are no comparable competitive Immunotherapy treatments.

Prostate Cancer Treatment Opportunities

1,100,000

161,360

~ 30 %

Globally there are 1.11 M new cases and 307,000 deaths.

In 2018, 164,650 men in the US will be diagnosed with prostate cancer and greater than 26,000 will die.

After initial treatment, about

20-30% of men will show signs of cancer recurrence.

 

THE PROBLEM

 

THE SOLUTION

Immunotherapy is the new solution – they only destroy antigen-expressing tumor cells and have no effect on normal cells

Kite Pharma Submits IND for BCMA-Targeting CAR-T Cancer Immunotherapy

Genetic Engineering & Biotechnology News

Aug 8, 2017

Please reload